[Cyclohexyl(piperidin-2-yl)methyl] acetate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: [Cyclohexyl(piperidin-2-yl)methyl] acetate
• 英文别名: [cyclohexyl(piperidin-2-yl)methyl] acetate
• 化学式: C₁₄H₂₅NO₂
• 分子量: 239.35
• InChiKey: LEMUONJQMPMKHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• NITROGEN-CONTAINING TRICYCLIC DERIVATIVE HAVING HIV REPLICATION INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP3305789A1

  公开（公告）日：2018-04-11

  The present invention provides a novel compound having antiviral activity, especially HIV replication inhibitory activity and a medicament containing the same. The compound represented by the formula: wherein A3 is CR3A, CR3A R3B, N or NR3C; R3A, R3B, R4A and R4B are each independently a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, or substituted or unsubstituted non-aromatic carbocyclyl; R3C is a hydrogen atom, substituted or unsubstituted alkyl, or substituted or unsubstituted non-aromatic carbocyclyl; ring T1 is substituted or unsubstituted nitrogen-containing non-aromatic heterocycle; R1 is a hydrogen atom, halogen, cyano, or substituted or unsubstituted alkyl; R2 is each independently substituted or unsubstituted alkyl or the like: n is 1 or 2; R3 is substituted or unsubstituted aromatic carbocyclyl or the like; R4 is a hydrogen atom or a carboxy protecting group.

  本发明提供了一种具有抗病毒活性的新型化合物，特别是具有抑制HIV复制活性的化合物和含有该化合物的药物。该化合物由以下式表示： 其中A3为CR3A、CR3A R3B、N或NR3C；R3A、R3B、R4A和R4B分别独立地为氢原子、卤素、氰基、取代或未取代的烷基、取代或未取代的炔基，或取代或未取代的非芳香碳环烷基；R3C为氢原子、取代或未取代的烷基，或取代或未取代的非芳香碳环烷基；环T1为取代或未取代的含氮非芳香杂环；R1为氢原子、卤素、氰基，或取代或未取代的烷基；R2分别为取代或未取代的烷基或类似物；n为1或2；R3为取代或未取代的芳香碳环烷基或类似物；R4为氢原子或羧基保护基。
• [EN] DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY<br/>[FR] DÉRIVÉS DE DIHYDROOXAZINE OU D'OXAZÉPINE AYANT UNE ACTIVITÉ INHIBITRICE DE BACE1
  申请人：SHIONOGI & CO

  公开号：WO2014065434A1

  公开（公告）日：2014-05-01

  The present invention provides a compound which has an effect of inhibiting amyloid beta production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid beta proteins. A compound of the formula (I):wherein X is -C(R3a)(R3b)-, -C(R3a)(R3b)-C(R3c)(R3d)- or -C(R3a)=C(R3c)-, R1 is substituted or unsubstituted alkyl or the like,R2a, R2b, R3a, R3b, R3c and R3d are each independently hydrogen, halogen or the like, R4 is hydrogen or halogen,Ring B is substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种化合物，具有抑制淀粉样蛋白β产生的作用，特别是抑制BACE1的作用，并且可用作治疗或预防由淀粉样蛋白β蛋白的产生、分泌和/或沉积引起的疾病的药剂。式(I)的化合物：其中X为-C(R3a)(R3b)-，-C(R3a)(R3b)-C(R3c)(R3d)-或-C(R3a)=C(R3c)-，R1为取代或未取代的烷基或类似物，R2a、R2b、R3a、R3b、R3c和R3d分别独立地为氢、卤素或类似物，R4为氢或卤素，环B为取代或未取代的碳环或取代或未取代的杂环，或其药学上可接受的盐。
• AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：US20150038483A1

  公开（公告）日：2015-02-05

  The present invention is related to a compound represented by formula (I) wherein R 1 is a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted aromatic carbocyclyl, or the like; X is —N(R 3 )—, —O—, or —S—; Y is ═C(R 4 )—, or ═N—; Z is —N(R 7 )—, —O—, or —S—; R 2 is substituted or unsubstituted alkyloxy, or the like, or a group represented by the following formula: —(CR 2a R 2b ) n —R 2c , wherein R 2a is each independently a hydrogen atom, halogen, or the like; R 2b is each independently a hydrogen atom, halogen, or the like; R 2a and R 2b which are attached to the same carbon atom may be taken together to form oxo, a substituted or unsubstituted non-aromatic carbocycle, or the like; two of R 2a which are attached to the adjacent carbon atoms and/or two of R 2b which are attached to the adjacent carbon atoms may be taken together to form a bond; R 2c is substituted or unsubstituted aromatic carbocyclyl, or the like; n is an integer from 1 to 3; R 3 and R 7 are each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; R 4 and R 5 are each independently a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like; R 6 is a hydrogen atom, halogen, substituted or unsubstituted alkyl, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

  本发明涉及一种由式（I）表示的化合物，其中R1是氢原子，取代或未取代的烷基，取代或未取代的芳香环烷基等；X是—N(R3)—，—O—或—S—；Y是═C(R4)—或═N—；Z是—N(R7)—，—O—或—S—；R2是取代或未取代的烷氧基等，或以下式表示的基团：—(CR2aR2b)n—R2c，其中R2a分别是氢原子，卤素等；R2b分别是氢原子，卤素等；附在同一碳原子上的R2a和R2b可以共同形成氧化物，取代或未取代的非芳香环烷基等；附在相邻碳原子上的两个R2a和/或附在相邻碳原子上的两个R2b可以共同形成键；R2c是取代或未取代的芳香环烷基等；n是1到3的整数；R3和R7分别是氢原子，取代或未取代的烷基等；R4和R5分别是氢原子，卤素，取代或未取代的烷基等；R6是氢原子，卤素，取代或未取代的烷基等，或其药学上可接受的盐，或包含其的药物组合物。
• [EN] A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN<br/>[FR] MÉDICAMENT DESTINÉ AU TRAITEMENT D'UNE INFECTION MYCOBACTÉRIENNE, CARACTÉRISÉ PAR LA COMBINAISON D'UN INHIBITEUR DE CYTOCHROME BC1 AVEC DE LA CLARITHROMYCINE OU DE L'AZITHROMYCINE
  申请人：SHIONOGI & CO

  公开号：WO2022119899A1

  公开（公告）日：2022-06-09

  A medicament characterized in that (A) a compound represented by formula (I):, or its pharmaceutically acceptable salt, wherein R1, R2, R3and R4are each independently hydrogen atom, halogen, hydroxy, cyano, substituted or unsubstituted alkyl or the like; R5is a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like; R6, R7, R8and R9are each independently hydrogen atom, halogen or the like; X is CH or N; Y is CH or N; R10is each independently halogen, hydroxy, cyano, substituted or unsubstituted alkyl or the like; m is 0, 1, 2, 3 or 4; R11is halogen, hydroxy, cyano, substituted or unsubstituted alkyl or the like; R12is each independently halogen, hydroxy, cyano or the like; n is 0, 1, 2, 3 or 4; is combined with (B) clarithromycin or its pharmaceutically acceptable salt, or azithromycin or its pharmaceutically acceptable salt; and (C) clofazimine, or its pharmaceutically acceptable salt.

  一种药物，其特点在于(A)化合物由式(I)表示，或其药学上可接受的盐，其中R1、R2、R3和R4分别独立地为氢原子，卤素，羟基，氰基，取代或未取代的烷基或类似物；R5为氢原子，卤素，氰基，取代或未取代的烷基或类似物；R6、R7、R8和R9分别独立地为氢原子，卤素或类似物；X为CH或N；Y为CH或N；R10分别独立地为卤素，羟基，氰基，取代或未取代的烷基或类似物；m为0，1，2，3或4；R11为卤素，羟基，氰基，取代或未取代的烷基或类似物；R12分别独立地为卤素，羟基，氰基或类似物；n为0，1，2，3或4；与(B)克拉霉素或其药学上可接受的盐，或阿奇霉素或其药学上可接受的盐结合；以及(C)克罗法齐明或其药学上可接受的盐。
• TRICYCLIC HETEROCYCLIC DERIVATIVE HAVING HIV REPLICATION-INHIBITING EFFECT
  申请人：Shionogi & Co., Ltd.

  公开号：EP3144311A1

  公开（公告）日：2017-03-22

  The present invention provides the following compound having anti-HIV activity of formula: wherein, A1 is C, CR1A or N; A2 is C, CR2A, or N; A3 is CR3A, CR3AR3B, N, NR3c O, S, SO, or SO2 ; A4 is CR4A, CR4AR4B, N, NR4C O, S, SO, or SO2; A5 is C, CR5A, or N; T1 ring is substituted or unsubstituted monocyclic carbocycle or substituted or unsubstituted monocyclic heterocycle; R1 is halogen, cyano, nitro or -X1-R11; R2 is substituted or unsubstituted alkyl and the like; n is 1 or 2; R3 is hydrogen, substituted or unsubstituted aromatic varbocyclyl; R4 is hydrogen or a carboxy protecting group; the other symbols are as specified in the description.

  本发明提供了以下具有抗艾滋病毒活性的式化合物： 其中，A1 是 C、CR1A 或 N； A2是C、CR2A或N A3 是 CR3A、CR3AR3B、N、NR3c O、S、SO 或 SO2 ； A4 是 CR4A、CR4AR4B、N、NR4C O、S、SO 或 SO2； A5 是 C、CR5A 或 N； T1 环是取代或未取代的单环碳环或取代或未取代的单环杂环； R1 是卤素、氰基、硝基或-X1-R11； R2 是取代或未取代的烷基等； n 是 1 或 2； R3 是氢、取代或未取代的芳香变环； R4 是氢或羧基保护基团； 其他符号如说明中所述。